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Traumatic brain injury (TBI) results in significant impairments in hippocampal synaptic
plasticity. A molecule critically involved in hippocampal synaptic plasticity, 3′,5′-cyclic
adenosine monophosphate, is downregulated in the hippocampus after TBI, but the
mechanism that underlies this decrease is unknown. To address this question, we
determined whether phosphodiesterase (PDE) expression in the hippocampus is altered
by TBI. Young adult male Sprague Dawley rats received sham surgery or moderate
parasagittal fluid-percussion brain injury. Animals were analyzed by western blotting for
changes in PDE expression levels in the hippocampus. We found that PDE1A levels
were significantly increased at 30 min, 1 h and 6 h after TBI. PDE4B2 and 4D2 were
also significantly increased at 1, 6, and 24 h after TBI. Additionally, phosphorylation of
PDE4A was significantly increased at 6 and 24 h after TBI. No significant changes were
observed in levels of PDE1B, 1C, 3A, 8A, or 8B between 30 min to 7 days after TBI.
To determine the spatial profile of these increases, we used immunohistochemistry and
flow cytometry at 24 h after TBI. PDE1A and phospho-PDE4A localized to neuronal cell
bodies. PDE4B2 was expressed in neuronal dendrites, microglia and infiltrating CD11b+
immune cells. PDE4D was predominantly found in microglia and infiltrating CD11b+
immune cells. To determine if inhibition of PDE4 would improve hippocampal synaptic
plasticity deficits after TBI, we treated hippocampal slices with rolipram, a pan-PDE4
inhibitor. Rolipram partially rescued the depression in basal synaptic transmission and
converted a decaying form of long-term potentiation (LTP) into long-lasting LTP. Overall,
these results identify several possible PDE targets for reducing hippocampal synaptic
plasticity deficits and improving cognitive function acutely after TBI.
Keywords: cAMP, CREB, fluid-percussion, hippocampus, inflammation, phosphodiesterase, traumatic brain
injury
INTRODUCTION
Every year in the United States an estimated 1.7 million people sustain a traumatic brain
injury (TBI) and nearly 70–80% of those who survive report chronic learning and memory
deﬁcits (Lew et al., 2006; Faul et al., 2010). The hippocampus is critically involved in learning
and memory and is highly susceptible to damage after TBI. Even when not directly damaged,
hippocampal atrophy and neuronal loss are often observed in TBI patients (Bigler et al., 1997;
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Tomaiuolo et al., 2004). This progressive hippocampal atrophy is
also observed in experimental models of TBI, and is accompanied
by a loss of dentate hilar cells and neurons in the CA3 region
as well as synaptic loss (Maxwell et al., 2003; Hall et al., 2005;
Scheﬀ et al., 2005; Witgen et al., 2005). In addition to these gross
morphological changes, in experimental models of TBI there are
deﬁcits in hippocampal basal synaptic transmission and long-
term potentiation (LTP; Miyazaki et al., 1992; Titus et al., 2013b).
Finding molecular targets to attenuate the damage caused by
TBI and improve hippocampal synaptic plasticity is of critical
importance to assist the estimated 3–5 million people currently
living with cognitive disabilities from TBI in the United States
(Langlois et al., 2006; Zaloshnja et al., 2008).
Targeting TBI-induced LTP deﬁcits is a promising strategy
for improving learning and memory (Atkins, 2011). During
hippocampal LTP and long-term memory formation, 3′,5′-
cyclic adenosine monophosphate (cAMP) signaling is critical to
activate the transcription factor cAMP-response element binding
protein (CREB) and mediate gene transcription required for
long-term memory formation (Frey et al., 1993; Bourtchuladze
et al., 1994). We have found that in an experimental model
of TBI, cAMP levels are depressed and CREB activation is
impaired during a learning task (Titus et al., 2013a,b). The exact
molecular mechanisms leading to the decrease in cAMP levels
and impairments in CREB activation after TBI are unknown.
cAMP is synthesized from ATP by adenylyl cyclases (ACs) and
cAMP signaling is tightly regulated in discrete spatial-temporal
microdomains through hydrolysis by phosphodiesterases (PDEs;
Houslay, 2010). Whether cAMP signaling in the hippocampus is
decreased after TBI by either changes in ACs or PDEs is unknown
and this knowledge could guide the development of therapeutic
strategies for treating the cognitive consequences of TBI.
One strategy for improving cAMP signaling is to inhibit
PDEs. However, an important consideration is that the PDE
superfamily is a large family of enzymes with 11 diﬀerent PDE
families (Bender and Beavo, 2006; Omori and Kotera, 2007).
Within each of the PDE families there are multiple subfamilies
encoded by individual genes, with several splice variants within
each subfamily. Eight of the PDE families hydrolyze cAMP:
PDEs 1, 2, 3, 10, and 11 hydrolyze both cAMP and cGMP,
and PDEs 4, 7, and 8 hydrolyze only cAMP (Maurice et al.,
2014). Of these PDEs, PDE1, 3, 4, 8, and 10 have been found
in the hippocampus (Johansson et al., 2012). The PDE1 family
consists of three subfamilies, PDE1A, 1B, and 1C, which are
encoded by separate genes. PDE1 is commonly referred to as
a Ca2+/calmodulin-stimulated PDE, and the activity of PDE1
can be enhanced through increases in calcium and calmodulin
signaling (Omori and Kotera, 2007; Heckman et al., 2015). The
PDE3 family consists of two subfamilies, PDE3A and 3B, which
are encoded by two separate genes. While PDE3 hydrolyzes
cAMP and cGMP, the ability for PDE3 to hydrolyze cAMP is
inhibited in the presence of cGMP (Bender and Beavo, 2006).
The PDE8 family is a cAMP-speciﬁc PDE that consists of two
subfamilies, PDE8A and 8B (Martinez and Gil, 2014). The PDE10
family is another dual-speciﬁc PDE which is encoded by one
gene, PDE10A (Kelly and Brandon, 2009). Given the wide array
of inhibitors that target each of these families, it is important to
understand how TBI aﬀects the expression and activity of each
these enzymes to target the relevant PDE (Menniti et al., 2006;
Spina, 2008; Titus et al., 2015b).
Of the cAMP-degrading PDEs, the most notable one in the
context of learning and memory is the PDE4 family (Li et al.,
2011; Heckman et al., 2015). The PDE4 family is encoded by four
genes, PDE4A, 4B, 4C, and 4D. With the exception of PDE4C, all
of these subfamilies are expressed in the brain, immune system
and cardiovascular system (Henkel-Tigges and Davis, 1990;
Reneerkens et al., 2009). A unique feature of the PDE4 family
is that they are further classiﬁed into four groups: long, short,
super-short, and dead-short isoforms (Titus et al., 2015a). This
classiﬁcation is based on the presence, or absence, of upstream
conserved regions (UCR) near the N-terminus, which allow
for diﬀerential post-translational regulation of these isoforms
(Hansen and Zhang, 2015). The PDE4A family has six isoforms:
PDE4A1, 4A4/5, 4A7, 4A8, 4A10, and 4A11. The PDE4B family
has ﬁve isoforms: PDE4B1-5. The PDE4D family has 10 isoforms:
4D1–7, 4D9, 4D10, and 4D11. Identifying the spatial and
temporal expression pattern of these PDEs in the hippocampus
after brain injury could facilitate the development of a more
targeted approach for reducing TBI-induced cognitive deﬁcits.
Targeting cAMP-degrading PDEs acutely after trauma has
yielded promising results in experimental models of spinal cord
injury and cerebral ischemia (Kato et al., 1995; Schaal et al.,
2012). However, pan-PDE inhibitors have broad eﬀects given
the widespread expression of PDE isoforms. In the context of
experimental TBI, the anti-inﬂammatory and neuroprotective
eﬀects of pan-PDE4 inhibitors are overshadowed by the
vasodilation and hemorrhagic eﬀects when administered acutely
after trauma (Atkins et al., 2012, 2013). This emphasizes the
need for more speciﬁc targets when treating the acute phase
of TBI. In a previous study, we reported that TBI alters PDE
expression in the ipsilateral parietal cortex acutely after trauma,
but whether similar changes occur in the hippocampus is
unknown (Oliva et al., 2012). Determining which PDEs are
upregulated after trauma could provide more speciﬁc drug
targets for reducing neuronal death, inﬂammation and atrophy
in the hippocampus after TBI. In this study we investigated
changes in PDE1, 3, 4, 8, and 10 after TBI using western blot




One hundred adult male Sprague Dawley rats were used in this
study (2–3 mos, 300–350 gm, Charles River Laboratories). All
experimental procedures were performed in accordance with
the NIH Guide for the Care and Use of Laboratory Animals
and with approval from the University of Miami Animal Care
and Use Committee. Animals were anesthetized (3% isoﬂurane,
70% N2O, 30% O2, 5 min) and received a 4.8 mm diameter
craniotomy at –3.8 mm posterior to bregma and 2.5 mm lateral
to the midline over the right parietal cortex. A plastic female
Luer Lock adapter (18 gage) was aﬃxed at the craniotomy site
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with cyanoacrylate and dental cement. Animals were allowed
to recover for 12–16 h while fasting with water ad libitum.
Animals were re-anesthetized (induction for 5 min with 3%
isoﬂurane, 70% N2O, 30% O2, maintenance during surgery with
1% isoﬂurane, 70% N2O, 30% O2), then intubated, mechanically
ventilated (Stoelting) and given rocuronium (10 mg/kg, intra-
arterial) and penicillin/benzathine (20,000 IU/kg, intramuscular).
Head and body temperature were maintained between 36.6
and 37.2◦C using rectal and temporalis muscle thermistors
connected to feedback-regulated heating lamps. Physiological
parameters (blood pO2 and pCO2, blood pH, and mean arterial
blood pressure) were monitored via a tail artery catheter and
maintained at normal levels throughout the surgery. Animals
were prospectively randomized into sham or TBI surgery groups.
Brain trauma was produced with a ﬂuid-pulse (16 ms duration,
2.0 ± 0.2 atmospheric pressure) at the craniotomy site. Sham-
operated animals received all surgical procedures identical to
the TBI animals with the exception of the ﬂuid-pulse. At the
end of the surgery, animals received buprenorphine (0.01 mg/kg,
subcutaneously). Criteria for exclusion from the study were:
mortality, >15% loss of body weight, non-resolving infection
at the surgical site, inability to feed or drink, motor paralysis,
listlessness, self-mutilation, excessive grooming leading to loss of
dermal layers, spontaneous vocalization when touched or poor
grooming habits. No animals were removed from the study. To
determine the number of animals needed for the study, a power
analysis was prospectively performed to detect a 50% diﬀerence
in PDE protein expression between groups with western blot
analysis at 80% power and signiﬁcance level of 0.05 (Oliva
et al., 2012). An n value of 6 animals/group was obtained.
Investigators were blind to the animal surgery treatment for the
electrophysiology analyses.
Western Blot Analysis
At 30 min, 1 h, 3 h, 6 h, 24 h, or 7 days after TBI or sham
surgery, animals were deeply anesthetized (3% isoﬂurane, 70%
N2O, 30% O2, 5 min) and decapitated (n = 6/time point for
TBI animals, n = 3/time point for sham animals). The ipsilateral
hippocampus was rapidly dissected on ice, snap frozen with
liquid nitrogen and stored at –80◦C. Tissue was homogenized
with a Dounce homogenizer (15 s, 4◦C) in: 15 mM Tris pH
7.6, 250 mM sucrose, 1 mM MgCl2, 1 mM EGTA, 1 mM
DTT, 0.5 mM PMSF, 0.1 mM Na3VO4, 50 mM NaF, 2 mM
Na4P2O7, 1.25 μg/ml pepstatin A, 10 μg/ml leupeptin, 25 μg/ml
aprotinin, and 1x phosphatase inhibitor cocktail set II (EMD
Millipore). Each hippocampus was homogenized in 750 μl of
buﬀer. Total protein was determined using Coomassie Plus
assay (Bio-Rad Laboratories). Homogenates were boiled with
sample buﬀer (9 min, 95◦C). Equal amounts of protein per
lane (60 μg/sample) were electrophoresed on 12.5% SDS-PAGE
gels. Proteins were transferred to Immobilon-P membranes
(EMD Millipore) and membranes were incubated with the
following primary antibodies: β-actin (AC-15, 1:10,000, Sigma–
Aldrich), PDE1A (sc-50480, 1:4,000, Santa Cruz Biotechnology),
PDE1B (ab14600, 1:500, Abcam; Giachini et al., 2011), PDE1C
(sc-67323, 1:500, Santa Cruz Biotechnology; Haering et al.,
2015), PDE3A (sc-20792, 1:250, Santa Cruz Biotechnology; Soler
et al., 2015), phospho-PDE4A (GTX14610, 1:2,000, GeneTex),
PDE4A5 (ab42094, 1:2,000, Abcam; Carito et al., 2012), PDE4A8
(GTX14606, 1:1,000, GeneTex), PDE4B (sc-25812, 1:500, Santa
Cruz Biotechnology; Suhasini et al., 2015), PDE4D (sc-25814,
1:500, Santa Cruz Biotechnology; Kunal et al., 2012), phospho-
PDE4D (ab59212, 1:1,000, Abcam), PDE8A (sc-30059, 1:500,
Santa Cruz Biotechnology; Dong et al., 2010), PDE8B (sc-17234,
1:500, Santa Cruz Biotechnology; Shimizu-Albergine et al., 2012),
and PDE10A (sc-67298, 1:250, Santa Cruz Biotechnology; Giralt
et al., 2013). These antibodies were chosen based on previously
published studies and resulted in bands that corresponded to
the appropriate, apparent molecular weights. Identiﬁcation of
speciﬁc PDE isoforms was based on known molecular weights.
Secondary antibodies conjugated to horseradish peroxidase were
used for detection (1:1,000, Cell Signaling Technology). Epitopes
were visualized with enhanced chemiluminescence or enhanced
chemiluminescence plus (GE Healthcare) and x-ray ﬁlm (Phenix
Research Products). Quantiﬁcation of ﬁlms was performed using
ImageJ 1.48v (NIH). Levels of each protein were normalized to
β-actin within each sample and then to the average of sham levels.
No signiﬁcant diﬀerences in PDE levels were observed in sham
animals at the diﬀerent survival time points (data not shown),
so the three sham animals at each recovery time point were
pooled into one sample for analysis to reduce animal numbers.
Representative western blots show sham animals taken from 3
and 24 h post-recovery.
Immunohistochemistry
Animals were deeply anesthetized (3% isoﬂurane, 70% N2O,
30% O2, 5 min) at 24 h after sham surgery (n = 3) or TBI
(n = 3) and perfused with saline (75 mL) and then with 4%
paraformaldehyde in PBS (350 mL, 4◦C). Brains were sectioned
with a vibratome (50 μm thick) and free ﬂoating sections were
blocked with PBS containing 5% normal goat serum, 0.2% ﬁsh
skin gelatin and 0.3% TX-100. Sections were incubated with the
following primary antibodies: PDE1A (sc-50480, 1 μg/ml, Santa
Cruz Biotechnology), phospho-PDE4A (GTX14610, 1 μg/ml,
GeneTex), PDE4B2 (ABS181, 2 μg/ml, Millipore; Ghosh et al.,
2012), PDE4D (ABS22, 2 μg/ml, Millipore; Kuroiwa et al., 2012),
MAP2 (M9942, 2 μg/ml, Sigma–Aldrich) and NeuN (MAB377,
4 μg/ml, Millipore). Primary PDE antibodies were selected based
on our western blot data demonstrating that these antibodies
recognized proteins of the appropriate known molecular weights.
Secondary antibodies used were conjugated to Alexa 488, Alexa
546 or Alexa 647 (Invitrogen). Cell nuclei were visualized using
Hoechst 33342 (Invitrogen).
Images were obtained with a FluoView FV1000 laser scanning
confocal microscope (Olympus America) equipped with a 10X
0.4 NA air objective, 20X 0.85 NA oil-immersion objective and
60X 1.42 NA oil-immersion objective, and an LD laser (405 nm),
multi-line argon laser and HeNe(G) laser. Sections from diﬀerent
animals were processed in parallel and at least three sections from
each animal were imaged.
Flow Cytometry
At 24 h after sham surgery (n = 6) or TBI (n = 6), animals
were deeply anesthetized (3% isoﬂurane, 70% N2O, 30% O2,
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5 min) and transcardially perfused with PBS (120 mL, 4◦C).
The ipsilateral hippocampus was dissected at 4◦C. Tissue was
mechanically dissociated into single cell suspension and cells
were labeled with CD45 Alexa 647 (202212, 1.25 μg/ml,
BioLegend) and CD11b v450 (53-4321-80, 1 μg/ml, eBioscience).
Dead cells were excluded using LIVE/DEAD Fixable Near-
IR dead cell stain (L10119, 1 μl/ml, Life Technologies).
Cells were ﬁxed and permeabilized with BD Cytoﬁx/Cytoperm
Fixation/Permeabilization kit (554714, BD Biosciences). Cells
were intracellularly labeled with phospho-PDE4A (GTX14610,
2 μg/ml, GeneTex), PDE4B2 (ABS181, 2 μg/ml, EMDMillipore)
or PDE4D (sc-25814, 2 μg/ml, Santa Cruz Biotechnology).
PDE staining was detected with PE-conjugated secondary
antibodies (12-4739-81, 10 μg/ml, eBioscience). Flow cytometry
data was acquired on a BD LSR II ﬂow cytometer with
four emission lasers at 407, 488, 532, and 640 nm. Data
collection was performed using BD FACSDiva 8.0.1 (BD
Biosciences) and analyzed with Kaluza 1.2 software (Beckman
Coulter).
FIGURE 1 | PDE expression changes after TBI in the hippocampus.
(A,C,E) Representative western blots of the ipsilateral hippocampus analyzed
for PDE1A, 1B, 1C, 3A, 8A, 8B, and 10A levels. Each of the corresponding
β-actin western blots are shown below the PDE western blots.
(B,D,F) Densitometry results. Significant increases in PDE1A were observed
at 30 min, 1 h and 6 h post-injury. PDE10A decreased at 1 h post-injury.
n = 6/group, ∗p < 0.05, ∗∗p < 0.01 vs. Sham; one-way ANOVA with Tukey’s
HSD correction for multiple comparisons.
Electrophysiology
At 24 h after sham surgery (n= 13) or TBI (n= 15), animals were
deeply anesthetized (3% isoﬂurane, 70% N2O, 30% O2, 5 min)
and then decapitated. The ipsilateral hippocampus was dissected
and sliced with a vibratome at 4◦C (Leica Microsystems). Slices
from the middle third of the hippocampus were collected
(400 μm thick) in artiﬁcial cerebral spinal ﬂuid (aCSF): 125 mM
NaCl, 2.5 mM KCl, 1.25 mM NaH2PO4, 25 mM NaHCO3,
10 mM D-glucose, 2 mM CaCl2, 1 mM MgCl2 saturated with
95% O2/5% CO2. Slices recovered at room temperature for at
least 60 min. Slices were transferred to a submerged recording
chamber and perfused at 2.5–3 ml/min with aCSF at 31◦C
(Warner Instruments). Field excitatory postsynaptic potentials
(fEPSPs) were recorded from the stratum radiatum of area CA1
with glass electrodes ﬁlled with 2 M NaCl (1–3 M). The
Schaﬀer collateral pathway was stimulated with a platinum-
iridium concentric bipolar electrode (tip diameter 25 μm, FHC).
Electrophysiological responses were recorded using aMulticlamp
700B ampliﬁer (Axon Instruments) and pClamp 10.4 software
(Axon Instruments). Recordings were low-pass ﬁltered at 2 kHz
and digitized at 20 kHz (Digidata 1440A, Molecular Devices).
Input–output (I–O) curves were generated with stepwise current
increases from 20 to 180 μA. Paired-pulse facilitation (PPF) was
measured with 50–250 ms stimulation intervals, delivered at a
current intensity of 40–50% of the maximum fEPSP. For baseline
responses prior to LTP induction, fEPSPs were recorded at a
current intensity of 40–50% of the maximum fEPSP, delivered at
0.033 Hz for at least 20 min. Long-term potentiation (LTP) was
induced with high frequency stimulation (HFS) of 100 Hz for 1 s
at the current intensity used for baseline stimulation. Rolipram
(3 μM) or vehicle (0.3% DMSO) were bath applied in aCSF
beginning 10 min prior to LTP induction and for 30 min after
tetanization. The amount of depolarization during tetanization
was analyzed by integrating the entire HFS response (total) or
integrating the last 50 ms of depolarization (steady-state; Klann
et al., 1998). Synaptic fatigue was calculated by normalizing each
fEPSP during tetanization to the ﬁrst fEPSP of the HFS (Rutten
et al., 2008b).
Data Analysis
Statistical comparisons were made using GraphPad Prism 6.05
or SigmaPlot 12.0 software. Western blot data and tetanization
responses were analyzed using a one-way ANOVA and Tukey’s
HSD correction for multiple comparisons. Flow cytometry data
was analyzed using an unpaired Student’s t-test. I–O responses,
PPF, and LTP data were analyzed using a repeated measures
two-way ANOVA and Tukey’s HSD correction for multiple
comparisons. Signiﬁcance was designated at p < 0.05. Results
presented are mean ± SEM.
RESULTS
We have previously reported that cAMP levels are decreased in
the hippocampus from 15 min to 4 h after TBI (Atkins et al.,
2007). To determine whether this decrease is associated with
changes in levels of PDE, the enzyme that degrades cAMP, we
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FIGURE 2 | Increased PDE4B2 and 4D2 expression in the hippocampus after TBI. (A,C,E) Representative western blots of the ipsilateral hippocampus
analyzed for changes in PDE4A, 4B, and 4D. (B,D,F) Densitometric analysis. Significant increases in phospho-PDE4A, and total levels of PDE4B2, 4D4, 4D3, and
4D2 were observed. Levels of PDE4B1/3 and 4B4 decreased after TBI. n = 6/group, ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 vs. Sham; one-way ANOVA with Tukey’s
HSD correction for multiple comparisons.
evaluated the hippocampus by western blot analysis for PDE
expression. We chose to evaluate PDE1, 3, 4, 8, and 10 since
these are either cAMP-speciﬁc or degrade both cAMP and cGMP
and are found in the brain or inﬂammatory cells that could
inﬁltrate the brain after injury (Boswell-Smith et al., 2006). At
30 min, 1 h, 3 h, 6 h, 24 h, or 7 days after moderate parasagittal
ﬂuid-percussion brain injury or sham surgery, animals were
analyzed by western blotting for changes in PDE expression in
the ipsilateral, injured hippocampus (Figure 1). We found that
PDE1A was signiﬁcantly increased as early as 30 min after TBI,
and remained elevated at 1 and 6 h post-injury. PDE1B and 1C
levels were unchanged after TBI between 30 min to 7 days post-
injury. No signiﬁcant changes in expression were also observed
for PDE3A, 8A, or 8B. PDE10A levels were unchanged with the
exception of a small decrease at 1 h post-injury.
PDE4 is the major cAMP-degrading enzyme in the brain and
the predominant PDE in inﬂammatory cells (Boswell-Smith et al.,
2006). PDE4A, 4B, and 4D are present in the brain, whereas
PDE4C is expressed only at very low levels in the brain (Perez-
Torres et al., 2000; Lakics et al., 2010; Johansson et al., 2012).
PDE4A and 4D are regulated by phosphorylation, and we found
that phosphorylation of PDE4A, but not 4D, was signiﬁcantly
increased at 6 and 24 h after TBI (Figures 2A,E). Total levels of
both PDE4A5 and 4A8 were unaltered after TBI (Figures 2A,B).
Levels of PDE4B1/3 were modestly, but signiﬁcantly decreased
at 6 and 24 h after TBI (Figures 2C,D). Similarly, PDE4B4 was
decreased at 24 h after injury. In contrast, both PDE4B2 and
4D2 were signiﬁcantly increased at 1, 6, and 24 h after TBI
(Figures 2D,F). PDE4D4 and 4D3 were also elevated at 24 h and
7 days post-injury, respectively (Figures 2E,F).
To determine the localization of these changes, we performed
immunohistochemistry at 24 h after TBI for PDE1A, phospho-
PDE4A, PDE4B2, and PDE4D4, the isoforms that showed the
largest changes in expression after TBI. PDE1A was found in
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FIGURE 3 | Immunohistochemistry of PDE1A in the hippocampus.
(A) The ipsilateral hippocampus was immunostained for PDE1A at 24 h after
TBI. PDE1A (green) colocalized to NeuN-positive cells (red) in area CA1. Scale
bar 50 μm. (B) Higher magnification of the ipsilateral CA1 pyramidal cell layer
(box). Scale bar 20 μm. (C) Expression of PDE1A in the contralateral
hippocampus in area CA1. Scale bar 50 μm. (D) PDE1A
immunohistochemistry in area CA1 from a sham animal. Scale bar 50 μm.
nuclei and neurites of neurons (Figure 3). Phospho-PDE4A
localized predominately to neuronal nuclei (Figure 4). In
contrast, PDE4B2 was expressed in dendrites as determined by
co-localization with MAP2, but not in the cell bodies or nuclei
(Figure 5). PDE4D immunoreactivity was present in scattered
cells throughout the hippocampus, suggestive of immune cell
inﬁltration (Figure 6).
To more deﬁnitively determine the cellular expression of
PDE4D, we performed ﬂow cytometry (Figure 7). We also
selected PDE4B2 and phospho-PDE4A for analysis since these
were also signiﬁcantly elevated in the injured hippocampus
at 24 h post-TBI and have been identiﬁed in immune cells
(Shepherd et al., 2004; Ghosh et al., 2012). Phospho-PDE4A,
PDE4B2, and 4D were localized to microglia and inﬁltrating
CD11b+/CD45+ immune cells in the hippocampus at 24 h post-
injury.
Next, to determine if upregulation of PDE4 expression is
involved in hippocampal synaptic plasticity deﬁcits after TBI,
we assessed whether administration of a pan-PDE4 inhibitor
would rescue the deﬁcits in hippocampal LTP induced by TBI.
Hippocampal LTP in area CA1 induced with a single tetanus was
signiﬁcantly impaired in slices from TBI animals (Figures 8A,B).
Rolipram (3 μM) applied to the hippocampal slices rescued
the deﬁcits in LTP expression [time × animal treatment
interaction F(177,2115) = 1.60, p < 0.001; Figures 8A,B]. Both
FIGURE 4 | Immunohistochemistry of phospho-PDE4A in the
hippocampus. (A) At 24 h after TBI, phosphorylated PDE4A (green) was
found throughout all subregions of the ipsilateral hippocampus and
colocalized with NeuN-positive cells (red). Scale bar 100 μm. (B) Higher
magnification of the ipsilateral CA3 pyramidal cell layer (box). Scale bar
20 μm. (C) Expression of phospho-PDE4A in the contralateral hippocampus.
Scale bar 100 μm. (D) Phospho-PDE4A immunohistochemistry in the sham,
non-injured hippocampus. Scale bar 100 μm.
FIGURE 5 | Immunohistochemistry of PDE4B2 in the hippocampus at
24 h after TBI. (A) PDE4B2 (green) colocalized to MAP2-positive dendrites
(red) throughout all subregions of the ipsilateral hippocampus. Scale bar
200 μm. (B) Higher magnification of the ipsilateral CA3 region (box). Scale bar
20 μm. (C) Expression of PDE4B2 in dendrites in the contralateral
hippocampus. Scale bar 200 μm. (D) PDE4B2 immunohistochemistry in area
CA3 from a sham animal. Scale bar 100 μm.
total and steady-state depolarization levels as well as synaptic
fatigue during tetanization were comparable between all groups,
suggesting that the impairment in LTP after TBI was not due to
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FIGURE 6 | Immunohistochemistry of PDE4D in the hippocampus at
24 h after TBI. (A) PDE4D (green) was found in scattered cells throughout all
regions of the ipsilateral hippocampus. Hoescht counterstaining was used to
identify the hippocampal pyramidal cell layers (blue). Scale bar 250 μm.
(B) Higher magnification of the ipsilateral dentate gyrus (box). Scale bar
20 μm. (C) Expression of PDE4D was at very low levels in the contralateral
hippocampus. Scale bar 250 μm. (D) PDE4D was present at very low levels in
the sham, non-injured hippocampus. Scale bar 250 μm.
diﬀerences in depolarization during the tetanus (Figures 8C,D).
To evaluate whether changes in basal synaptic transmission
were involved in the rescue of hippcampal LTP, we analyzed
input–output (I–O) responses. I–O curves were signiﬁcantly
depressed in slices from TBI animals as compared to sham
animals [stimulation intensity × animal treatment interaction
F(24,288) = 2.76, p < 0.001]. This depression in basal synaptic
transmission was partially rescued with rolipram [main eﬀect of
animal treatment F(3,288) = 8.12, p < 0.001; Figures 9A,B]. PPF
was depressed after TBI and also partially rescued with rolipram
treatment [main eﬀect of animal treatment F(3,144) = 3.35,
p < 0.05; Figure 9C]. These results indicate that hippocampal
basal synaptic transmission and LTP expression in area CA1
were impaired acutely after TBI and rescued with the pan-PDE4
inhibitor, rolipram.
DISCUSSION
Downregulation of the cAMP signaling pathway following TBI
signiﬁcantly alters hippocampal synaptic plasticity, however, the
underlying mechanisms are unknown. The PDE enzymes play
a critical role in the regulation of cAMP levels, and alterations
in PDE expression and phosphorylation may be involved in
the depression of cAMP levels following TBI. Therefore, in the
present study we evaluated whether expression of PDEs such as
PDE1, 3, 4, 8, and 10, which are present in the central nervous
system and hydrolyze cAMP, were altered acutely after TBI
(Bender and Beavo, 2006; Omori and Kotera, 2007; Lakics et al.,
2010). While not all PDE isoforms showed altered expression
levels, several were signiﬁcantly changed. PDE1A, 4B2, and 4D2,
and phosphorylation of PDE4A were signiﬁcantly upregulated,
whereas PDE4B1/3, 4B4, and 10A levels decreased acutely
after TBI. The PDEs 1B, 1C, 3A, 4A5, 4A8, 8A, and 8B, and
phospho-PDE4D were unchanged acutely after TBI. Although
an a priori power analysis was conducted to ensure the sample
sizes were suﬃcient to detect signiﬁcant changes in PDE levels
after TBI, for these particular PDEs the negative results should be
interpreted cautiously.
Phosphodiesterases are key enzymes involved in regulating
cAMP levels in the central nervous system. Understanding the
spatio-temporal alterations in PDE isoform expression levels after
injury is important for targeting the relevant isoform as well as
treating within the appropriate therapeutic time window. In a
previous study, we found that there were signiﬁcant temporal
changes in PDE expression within the ipsilateral cortex acutely
after TBI (Oliva et al., 2012). Like the present results found in
the injured hippocampus, TBI induced upregulation of PDE1A,
4B2, and 4D2 in the ipsilateral cortex. However, not all PDEs
were regulated similarly between the cortex and hippocampus.
For example, PDE10A was upregulated in the cortex, but
downregulated in the hippocampus acutely after TBI. PDE4A5
and 4A8 were downregulated in the cortex, but unaltered in
the hippocampus. Furthermore, both PDE4D4 and 4D3 were
upregulated at 24 h after TBI in the hippocampus, but unchanged
in the cortex. These discrepancies suggest that developing a
therapeutic to target a speciﬁc PDE and particular functional
outcome requires consideration of both the temporal and spatial
regulation of that particular PDE isoform.
The upregulation of PDE1A in the hippocampus after TBI
suggests that beyond decreasing cAMP levels, cGMP levels may
also be aﬀected by TBI. PDE1 is a family of Ca2+/calmodulin-
dependent PDEs encoded by three genes (A–C) and involved
in the regulation of both cGMP and cAMP (Bender and Beavo,
2006). In the human brain, PDE1A is distributed in the parietal
cortex and hippocampus, but at lower levels than PDE1B or
1C (Lakics et al., 2010). In the present study, expression of
PDE1A was signiﬁcantly increased, while PDE1B and 1C were
unchanged after TBI. Although the PDE1 family uses both cyclic
nucleotides as a substrate, PDE1A displays a higher aﬃnity
toward cGMP than cAMP (Bender and Beavo, 2006). Conversely,
PDE10A which is also a dual-substrate PDE, was downregulated
in the hippocampus. These opposing changes may be involved
in the lack of changes in basal cGMP levels reported in the
hippocampus after TBI (Temple et al., 2001). However, NMDA-
stimulated levels of cGMP are actually increased in the ipsilateral
hippocampus after TBI and further studies are required to
determine if cGMP-selective PDEs expressed in the brain such
as PDE9 are altered by TBI (Temple et al., 2001). Together these
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FIGURE 7 | Flow cytometry of microglia and infiltrating CD11b+ immune cells and co-localization with phospho-PDE4A, PDE4B2, and 4D.
(A) Phospho-PDE4A, (C) PDE4B2, and (E) PDE4D expression were localized to microglia and infiltrating immune cells in the injured hippocampus at 24 h post-injury.
There was a significant increase in (B) phospho-PDE4A, (D) PDE4B2 and (F) PDE4D-positive infiltrating CD11b+/CD45+ immune cells. n = 6/group, ∗∗∗p < 0.001
vs. Sham; unpaired Student’s t-test.
results support the potential therapeutic use of PDE1 inhibitors
such as vinpocetine, amantadine and caﬀeine, which have shown
promise to improve cognitive impairments in preclinical models
of TBI and in humans (Dixon et al., 1999; Li et al., 2008; Amen
et al., 2011).
In particular, the PDE4 family was highly regulated in
the hippocampus after TBI. PDE4B2, 4D2, 4D3, and 4D4
expression levels and phosphorylation of PDE4A were increased
following TBI, while PDE4B1/3 and 4B4 levels were decreased.
Due to the similar molecular weights of PDEB1 and B3, we
were unable to diﬀerentiate which particular isoform decreased
after TBI. The changes in PDE4 isoforms were transient with
most returning to sham, non-injured levels by 7 days post-
injury. The upregulation of PDE4 isoforms correlates loosely
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FIGURE 8 | PDE4 inhibition significantly rescued TBI-induced LTP
deficits in area CA1 of the hippocampus. (A) Representative traces of the
fEPSP before (black) and 60 min after (red) tetanization. (B) fEPSP slopes
were normalized to baseline prior to LTP induction. Rolipram (3 μM) or vehicle
(0.3% DMSO) were bath applied 10 min prior to and for 30 min after
tetanization (bar). Hippocampal LTP was induced with 1 × 100 Hz
tetanization, 1 s long (arrow). (C) Total and steady-state depolarization levels
during tetanization. (D) Synaptic fatigue during tetanization. Sham + Vehicle
n = 10 slices/9 animals, Sham + Rolipram n = 14 slices/12 animals,
TBI+Vehicle n = 8 slices/7 animals, TBI+Rolipram n = 8 slices/8 animals;
∗∗∗p < 0.001 vs. Sham + Vehicle or Sham + Rolipram, ap < 0.05 vs.
TBI + Rolipram; repeated-measures two-way ANOVA with Tukey’s HSD
correction for multiple comparisons.
with the decrease in cAMP levels and PKA activation after
TBI (Atkins et al., 2007). However, a causal link between an
upregulation of PDE4 expression and decreased cAMP levels has
not been established. Alternatively, changes in AC activity or
expression could be involved in the decrease in cAMP levels after
TBI. Accordingly, reduction in type 1 AC enzyme levels have
been reported within the hippocampus of Alzheimer’s disease
patients, aged rodents and after ischemia, and are correlated
with impairments in cAMP signal transduction (Araki et al.,
1995; Yamamoto et al., 2000; Nagakura et al., 2002; Ramos
et al., 2003; Mons et al., 2004). Further studies are needed to
FIGURE 9 | Effects of rolipram on hippocampal synaptic transmission
at 24 h post-TBI. (A) Representative traces of the fEPSP evoked during
input–output (I–O) responses in stratum radiatum of area CA1 with Schaffer
collateral stimulation. (B) The I–O curve was significantly shifted downward in
hippocampal slices from TBI animals as compared to sham animals. Rolipram
(3 μM) significantly enhanced the fEPSP slope in slices from TBI animals.
∗p < 0.05, ∗∗∗p < 0.001 vs. Sham + Vehicle, #p < 0.01 vs. TBI + Rolipram,
ap < 0.05 vs. Sham + Vehicle. (C) A decrease in PPF was observed in
TBI + Vehicle-treated slices (p < 0.05 TBI + Vehicle vs. Sham + Vehicle) that
was not significant in TBI + Rolipram-treated slices. Data represent the ratio
of the second fEPSP slope to the first fEPSP slope. Sham + Vehicle n = 10
slices/9 animals, Sham + Rolipram n = 14 slices/12 animals, TBI+Vehicle
n = 8 slices/7 animals, TBI + Rolipram n = 8 slices/8 animals;
repeated-measures two-way ANOVA with Tukey’s HSD correction for multiple
comparisons.
determine if AC levels are also altered by TBI or whether the
increase in PDE expression after TBI also results in increased
PDE activity.
The PDE4 subfamily, like other PDEs, is subject to post-
translational modiﬁcation to allow for rapid feedback in
controlling the spatial and temporal dynamics of cAMP
signaling (Houslay, 2010). Unlike the other PDE4 isoforms,
the long isoforms have a UCR1 domain that contains a PKA
phosphorylation site that enhances PDE4 activity (Mackenzie
et al., 2002). The PKA phosphorylation site allows for cAMP
signaling to negatively feedback on itself through enhanced
activation of long PDE4A isoforms. PDE4A5 and 4A8 are
both long isoforms with similar molecular weights, which
precluded deﬁnitively identifying which isoform was increased
in phosphorylation after TBI. Phospho-PDE4A localized to
both hippocampal neurons and inﬁltrating CD11b+ leukocytes.
While this increase in phospho-PDE4A is indicative of an
increase in PKA-mediated PDE4A activity, the timing of this
change does not correlate with changes seen in cAMP and
phospho-PKA, which are depressed in the hippocampus during
this time frame (Atkins et al., 2007). However, it is possible
that there could be changes in cAMP and PKA signaling
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in microdomains mediating this eﬀect that were missed
with the western blot analysis or immunohistochemistry.
Subcellular, compartmentalized signaling changes have
been reported when assessing diﬀerences between PDE4B
and 4D signaling (Blackman et al., 2011). An alternative
possibility was that another protein kinase mediated this
phosphorylation, such as MAPK-activated protein kinase
2, which has been reported to phosphorylate a serine near
the PKA phosphorylation site of PDE4A5 (Mackenzie et al.,
2011).
In contrast to the results with phospho-PDE4A, the increase
in PDE4B2 and 4D2 expression correlated with the decrease in
cAMP levels after TBI (Atkins et al., 2007). Within 1 h after
trauma, PDE4B2 and 4D2 were signiﬁcantly elevated in the
injured hippocampus and remained elevated for up to 24 h post-
injury. Although the immunohistochemistry results indicated
that PDE4B2 and phospho-PDE4A localized to neurons, ﬂow
cytometry revealed expression of PDE4B2 and phospho-PDE4A
in microglia and inﬁltrating CD11b+/CD45+ leukocytes as
well. The absence of obvious expression in microglia or
inﬁltrating immune cells with immunohistochemistry suggests
that phospho-PDE4A- and PDE4B2-positive immune cells may
be present near the contusion site between the parietal cortex
and hippocampus which was likely sampled in the western blot
analysis. Immunohistochemistry of this damaged area can be
hindered by autoﬂuorescence of red blood cells present at the
contusion site. These ﬁndings are supported by other studies
which have found that both isoforms are diﬀerentially distributed
throughout the brain and also found in the immune system.
PDE4B and 4D are present in monocytes, macrophages and
neutrophils and regulate pro-inﬂammatory mediators such as
tumor necrosis factor and neutrophil inﬁltration (Jin and Conti,
2002; Ariga et al., 2004; Shepherd et al., 2004). Interestingly,
phospho-PDE4A and PDE4D were expressed in a larger
proportion of inﬁltrating CD11b+/CD45+ cells as compared
to PDE4B2. While the increase in phospho-PDE4A, PDE4B2,
and PDE4D in immune cells may contribute to inﬂammatory
signaling after TBI, the upregulation of PDE4B2 in hippocampal
dendrites suggests that this molecule may have multiple roles in
TBI and may also be involved in learning and memory deﬁcits
after TBI.
PDE4 is well known to be involved in hippocampal LTP and
long-term memory formation (Navakkode et al., 2004; Rutten
et al., 2008a,b; Li et al., 2011). General pan-PDE4 inhibitors such
as rolipram reverse learning and memory impairments in animal
models of Alzheimer’s disease, psychosis, stress, and ischemia
(Henkel-Tigges and Davis, 1990; Imanishi et al., 1997; Bach et al.,
1999; Gong et al., 2004; Chen et al., 2010; Wiescholleck and
Manahan-Vaughan, 2012; Sierksma et al., 2014). In accordance
with these previous studies, we found that bath application of
rolipram to hippocampal slices from TBI animals reversed the
decay of LTP (Navakkode et al., 2004). However, the dose of
rolipram required to rescue hippocampal LTP (3 μM) at 24 h
post-injury was threefold greater than the dose suﬃcient to
rescue hippocampal LTP deﬁcits at 2 weeks post-injury (1 μM;
Titus et al., 2013a,b). Indeed, 1 μM rolipram did not rescue
the deﬁcits in hippocampal LTP at 24 h post-injury (data not
shown). Given that expression of most PDE4 isoforms returned
to sham, non-injured levels by 7 days post-injury, we speculate
that the acute, transient upregulation of PDE4 isoforms at
24 h post-injury resulted in the necessity for a higher dose of
rolipram to rescue hippocampal LTP deﬁcits at this acute time
point.
Interestingly, rolipram also partially improved the depression
of basal synaptic transmission in area CA1 of the hippocampus.
Basal synaptic transmission in the hippocampus is mediated
primarily through AMPA-type glutamate receptors, which are
well known to be regulated by PKA (Man et al., 2007). Traﬃcking
of AMPA-type glutamate receptors into the postsynaptic
membrane is increased by PKA phosphorylation of serine 845
on the GluA1 subunit (Oh et al., 2006; Middei et al., 2013).
GluA1 levels have been found to be altered in some experimental
models of TBI (Schumann et al., 2008; Kharlamov et al., 2011).
The observed partial rescue in basal synaptic transmission may
possibly be through regulation of AMPA receptor traﬃcking
although further studies are needed to evaluate this potential
mechanism.
In summary, we found that in an experimental model of
TBI there was an acute upregulation of PDE1A, 4B2, 4D4,
4D3, 4D2, and phosphorylated PDE4A in the hippocampus
after injury. Furthermore, we found that PDE4B2 and phospho-
PDE4A were localized to neurons, microglia and inﬁltrating
CD11b+ leukocytes in the injured hippocampus early after
trauma. PDE4D was found predominantly in microglia and
inﬁltrating CD11b+/CD45+ leukocytes. Rolipram, a pan-PDE4
inhibitor, rescued synaptic plasticity deﬁcits in the hippocampus
at 24 h after TBI. Given the role of these PDE4 subfamilies
in learning, memory and inﬂammation, this study highlights
new potential targets for reducing damage and improving
hippocampal synaptic plasticity after TBI.
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